These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9808919)

  • 1. Extreme reduction of methylphenidate levels by carbamazepine.
    Behar D; Schaller J; Spreat S
    J Am Acad Child Adolesc Psychiatry; 1998 Nov; 37(11):1128-9. PubMed ID: 9808919
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbamazepine and methylphenidate.
    Gross-Tsur V
    J Am Acad Child Adolesc Psychiatry; 1999 Jun; 38(6):637. PubMed ID: 10361775
    [No Abstract]   [Full Text] [Related]  

  • 3. Polypharmacy side effects.
    Markowitz J; Patrick K
    J Am Acad Child Adolesc Psychiatry; 1996 Jul; 35(7):842. PubMed ID: 8768342
    [No Abstract]   [Full Text] [Related]  

  • 4. Flawed attention-deficit/hyperactivity disorder medication comparison.
    Adesman A
    Pediatrics; 2004 Oct; 114(4):1132; author reply 1132-3. PubMed ID: 15466129
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxicokinetic assessment of methylphenidate (Ritalin(R)) in a 13-week oral (gavage) toxicity study in rats using an enantiomeric liquid chromatography/tandem mass spectrometry assay.
    Bakhtiar R; Tse FL
    Rapid Commun Mass Spectrom; 2003; 17(18):2160-2. PubMed ID: 12955748
    [No Abstract]   [Full Text] [Related]  

  • 6. [Attention deficit hyperactivity disorder in children].
    Bervoets L
    J Pharm Belg; 2002; 57(2):25-32. PubMed ID: 12053824
    [No Abstract]   [Full Text] [Related]  

  • 7. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
    Aanonsen NO
    Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
    J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute liver failure caused by isoniazid in a child receiving carbamazepine.
    Berkowitz FE; Henderson SL; Fajman N; Schoen B; Naughton M
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):603-6. PubMed ID: 9661830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.
    Modi NB; Wang B; Noveck RJ; Gupta SK
    J Clin Pharmacol; 2000 Oct; 40(10):1141-9. PubMed ID: 11028253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia].
    Alegre Herrera S; Araujo Sanabria J; Rubio Rubio JM
    An Med Interna; 1998 Jan; 15(1):48-9. PubMed ID: 9522506
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical inquiries. Does increasing methylphenidate dose aid symptom control in ADHD?
    Ibay AD; Bascelli LM; Graves RS; Hill J
    J Fam Pract; 2003 May; 52(5):400, 403. PubMed ID: 12737774
    [No Abstract]   [Full Text] [Related]  

  • 19. Need for bedtime dose of ritalin.
    Rogers WB
    Pediatrics; 1996 Aug; 98(2 Pt 1):314. PubMed ID: 8692642
    [No Abstract]   [Full Text] [Related]  

  • 20. Reproductive toxicology. Methylphenidate hydrochloride.
    Environ Health Perspect; 1997 Feb; 105 Suppl 1(Suppl 1):319-20. PubMed ID: 9114343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.